2024-05-03 13:45:54 ET
Summary
- The FTC is investigating improper patent listings, including Novo Nordisk's Ozempic, which could impact shareholders.
- Novo Nordisk's GLP-1 agonists, including Ozempic, have become a significant part of the company's revenue.
- The scrutiny from the FTC and Congress on pharmaceutical companies' competitive practices may pose risks for Novo Nordisk shareholders.
- Furthermore, intense competition is coming for market share, particularly from Eli Lilly.
- In total, the risks outweigh the rewards for Novo Nordisk.
...
Read the full article on Seeking Alpha
For further details see:
The FTC Cracks Down On Novo Nordisk's Ozempic